Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Muscarinic Agonist Modulation of Memory Processing Oscillatory Activity
NCT07228338Phase 1Not yet recruiting
- Sponsor
- UT Southwestern Medical Center
- Start
- Dec 2026
- Primary completion
- Dec 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of trospium in memory disorder and cognitive impairment (2 arms), sponsored by UT Southwestern Medical Center. Primary endpoint: Memory-related changes in brain electrical activity at Day 2. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
trospium
03
Conditions
memory disordercognitive impairment
Beyond the preview
Go deeper on NCT07228338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07228338.